Literature DB >> 8419147

Characterization of the 1,25-(OH)2D3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells.

H Ishida1, C G Bellows, J E Aubin, J N Heersche.   

Abstract

We investigated the effects of 1,25-dihydroxyvitamin D3[1,25-(OH)2D3], on osteoprogenitor cell differentiation and bone nodule formation at various stages of differentiation by evaluating the effects on long term cultures of fetal rat calvaria (RC) cells. RC cells were plated at 3 x 10(4) cells/35-mm dish in alpha-minimal essential medium containing 15% fetal bovine serum, ascorbic acid, and beta-glycerophosphate (beta-GP), conditions under which bone nodules form. 1,25-(OH)2D3 inhibited bone nodule formation in a dose-dependent manner with total inhibition occurring at 1-10 nM and half-maximal inhibition occurring at approximately 0.06 nM. 1,25-(OH)2D3 also significantly stimulated RC cell growth in a dose-dependent manner in both the presence and absence of ascorbic acid. Addition of 1 nM 1,25-(OH)2D3 at different times after the start of culture inhibited nodule formation when added before and up to the early multilayering stage (up to day 11 of culture), but had no effect on nodule number when added later. When 1,25-(OH)2D3 was added at the start of the culture period and removed at the early multilayering stage, nodule formation was also inhibited. Pulses of 48-h duration also inhibited nodule formation, with maximal effect occurring between days 3 and 11. Thus, 1,25-(OH)2D3 inhibited osteoprogenitor cell differentiation during the earlier stages of culture before visible bone nodule formation occurred and the effect was not reversible upon removal of 1,25-(OH)2D3. In cultures grown to the multilayering stage in medium without ascorbic acid and beta-GP and then changed to medium with ascorbic acid and beta-GP, 1,25-(OH)2D3 inhibited when present before, but not after, the addition of ascorbic acid and beta-GP. Two other vitamin D3 metabolites, 24,25-dihydroxyvitamin D3 [24,25-(OH)2D3] and 1,24,25-trihydroxyvitamin D3 [1,24,25-(OH)3D3] had inhibitory effects similar to 1,25-(OH)2D3. The effects were dose dependent for each metabolite tested and correlated with the biological effectiveness of these metabolites in other systems: i.e. 1,25-(OH)2D3 was more effective than 1,24,25-(OH)3D3 which in turn was more effective than 24,25-(OH)2D3. The data show that 1,25-(OH)2D3 inhibits osteoprogenitor cell differentiation at an early stage and at a time during which cell growth is stimulated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419147     DOI: 10.1210/endo.132.1.8419147

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo.

Authors:  D D Dean; B D Boyan; Z Schwart; O E Muniz; M R Carreno; S Maeda; D S Howell
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  1,25-Dihydroxyvitamin D3 induces expression of the Wnt signaling co-regulator LRP5 via regulatory elements located significantly downstream of the gene's transcriptional start site.

Authors:  Jackie A Fretz; Lee A Zella; Sungtae Kim; Nirupama K Shevde; J Wesley Pike
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-16       Impact factor: 4.292

3.  Vitamin D endocrine system and osteoblasts.

Authors:  Marjolein van Driel; Johannes P T M van Leeuwen
Journal:  Bonekey Rep       Date:  2014-02-05

4.  Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene.

Authors:  R H Kim; J J Li; Y Ogata; M Yamauchi; L P Freedman; J Sodek
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

5.  A new method for the preparation of bioactive calcium phosphate films hybridized with 1alpha,25-dihydroxyvitamin D3.

Authors:  Jae-Young Jung; Yun-Jung Hong; Yong Seok Choi; Sunjoo Jeong; Woo-Kul Lee
Journal:  J Mater Sci Mater Med       Date:  2009-12       Impact factor: 3.896

6.  Osteogenic Effect of Fisetin Doping in Bioactive Glass/Poly(caprolactone) Hybrid Scaffolds.

Authors:  Henri Granel; Cédric Bossard; Anne-Margaux Collignon; Fabien Wauquier; Julie Lesieur; Gael Y Rochefort; Edouard Jallot; Jonathan Lao; Yohann Wittrant
Journal:  ACS Omega       Date:  2022-06-21

7.  Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D(3) stimulation.

Authors:  N Maruotti; A Corrado; M Grano; S Colucci; F P Cantatore
Journal:  Rheumatol Int       Date:  2008-11-07       Impact factor: 2.631

8.  Effect of prostaglandin E2 on mineralization of bone nodules formed by fetal rat calvarial cells.

Authors:  T Nagata; K Kaho; S Nishikawa; H Shinohara; Y Wakano; H Ishida
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

9.  Generation and characterization of two immortalized human osteoblastic cell lines useful for epigenetic studies.

Authors:  Flor M Pérez-Campo; Tobias May; Jeannette Zauers; Carolina Sañudo; Jesús Delgado-Calle; Jana Arozamena; María T Berciano; Miguel Lafarga; José A Riancho
Journal:  J Bone Miner Metab       Date:  2016-04-02       Impact factor: 2.626

10.  Contiguous 22.1-kb deletion embracing AVPR2 and ARHGAP4 genes at novel breakpoints leads to nephrogenic diabetes insipidus in a Chinese pedigree.

Authors:  Ying Bai; Yibing Chen; Xiangdong Kong
Journal:  BMC Nephrol       Date:  2018-02-02       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.